Overview

Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)

Status:
Completed

Trial end date:
2012-07-01

Target enrollment:

Participant gender:

Summary

Study is to assess if TC-5619 improves symptoms for adults diagnosed with the inattentive-predominant subtype of ADHD over a 4-week treatment period.

Phase:

Phase 2

Details

Lead Sponsor:

Targacept Inc.